Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Liminal BioSciences Announces Strategic Priorities For 2022

<< Previous

Bullboard Posts

Next >>

Comment by stockbuphoonon Jan 19, 2022 9:53pm

145 Views

Post# 34335829

RE:Liminal BioSciences Announces Strategic Priorities For 2022

Results on 4050 Delayed another quarter - "penicillin" just not cutting it as thomvest creates perception of total failure of 4050 in telegraphed series of press releases. Clearly headed for a financing accomplishing nothing over past year. Who wins? Thomvest again. Silently take over 4050 and sell privately in 3 years under the cover of night. Wait for it.